Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
Incyte Corp reported that Principal Accounting Officer Tray Thomas received equity awards on July 16, 2026. He was granted 2,834 restricted stock units (RSUs), vesting 25% annually over four years, and 4,079 employee stock options with a $116.65 exercise price, expiring July 15, 2036, vesting 25% after one year then monthly over three years. Following these grants he directly holds 21,699 common shares, including 13,070 shares issuable from previously reported unvested RSUs.
Steven H. Stein, Incyte's CMO and Head of Late-Stage Development, reported July 16, 2026 equity activity including grants of 9,798 restricted stock units, 24,496 performance shares, and 42,298 stock options with an exercise price of 116.6500 per share, plus a sale of 1,877 common shares at 114.7300 per share. These transactions were made under a Rule 10b5-1 trading plan. The RSUs vest 25% annually over four years, the options vest over four years in 37 installments, and performance shares may earn up to 200% of one share based on three-year relative TSR versus a peer group.
Mayes Patrick A reported acquisition or exercise transactions in this Form 4 filing.
Incyte Corp EVP & Chief Scientific Officer Patrick A. Mayes received equity awards on July 16, 2026, including 5,916 restricted stock units vesting 25% annually over four years, 25,538 stock options at $116.65 per share expiring July 15, 2036, and 14,790 performance shares tied to relative total shareholder return over a three-year period. Following the RSU award, he directly holds 63,628 shares of common stock.
INCYTE CORP’s President, Global Head of R&D Pablo J. Cagnoni received equity compensation awards on July 16, 2026, including 13,403 restricted stock units, 57,861 employee stock options at an exercise price of $116.65 per share, and 33,508 performance shares.
After these awards, he directly holds 231,332 common shares, including 183,200 shares issuable under unvested restricted stock units and earned performance stock units. The RSUs vest 25% annually over four years, options vest over four years, and performance shares may deliver up to 200% of a share based on three-year relative TSR.
INCYTE CORP executive Mohamed Khairie Issa, EVP and Head of U.S. Commercial, reported equity grants and a small stock sale. He received 7,857 restricted stock units vesting 25% annually over four years, for a total of 71,797 unvested RSU-based shares, plus 33,918 stock options at an exercise price of $116.65 and 19,643 performance shares linked to relative total shareholder return. On the same date, he sold 1,093 common shares at $115.01, leaving 63,940 shares held directly. The filing indicates these transactions were effected under a Rule 10b5-1 trading plan.
Incyte Corp EVP, Human Resources Ramitpal K. Basi received multiple equity awards. On July 16, 2026, he was granted 4,991 restricted stock units vesting 25% annually over four years, 21,548 employee stock options with a $116.65 exercise price vesting over four years, and 12,479 performance shares that may deliver up to 200% of one share each based on relative total shareholder return over a three-year period. In total, 11,497 shares of common stock are issuable upon vesting of his outstanding restricted stock units.
Gardner David H reported acquisition or exercise transactions in this Form 4 filing.
Incyte EVP and Chief Strategy Officer David H. Gardner received equity awards on July 16, 2026, including 7,395 restricted stock units, 31,923 employee stock options at $116.65 per share, and 18,487 performance shares tied to Incyte common stock.
The RSUs vest 25% annually over four years, the options become exercisable 25% after one year and then monthly over three years, and the performance shares can deliver up to 200% of a share each based on three-year TSR performance, with earned shares vesting on the third anniversary of the grant.
INCYTE CORP executive Richard A. Hoffman, EVP & General Counsel, received multiple equity awards on July 16, 2026. He was granted 7,395 restricted stock units vesting 25% annually over four years, bringing unvested RSU-linked common shares to 16,861. He also received options on 31,923 shares at an exercise price of $116.65 expiring July 15, 2036, vesting 25% after one year and then monthly over three years, plus 18,487 performance shares that can pay up to 200% of one common share each based on relative TSR over a three-year period starting January 1, 2026.
INCYTE CORP Chief Executive Officer William Meury received multiple equity awards on July 16, 2026. He was granted 26,807 restricted stock units that vest 25% annually over four years, 77,148 stock options with a $116.65 exercise price, and 80,421 performance shares that can deliver up to 200% of one share each based on relative total shareholder return over a three-year period.
Following these awards, his direct common stock exposure totals 183,129 shares, including 178,883 shares issuable from previously reported unvested restricted stock units and earned performance stock units.
Steven Stein submitted a Form 144 notice covering a planned sale of 1,877 shares of INCY common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The securities are described as restricted stock and are expected to be sold around 07/16/2026 on NASDAQ, with an associated amount of 215,339.39.
The notice also lists sales during the past three months, including 28,237 shares of INCY common stock sold on 07/15/2026 with a total amount of 3,192,254.97.